NCT07742917Recruiting
Precision Lifestyle Medicine Program for IFHAS Participants
Application of a Precision Lifestyle Medicine Clinical Program for a Sample of IFHAS Screening Cohort
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are: * Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention? * Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population? Researchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health. Participants will: * Take part in an 18-week personalized lifestyle medicine program tailored to their health profile. * Attend study visits and complete health assessments over a total study period of 24 weeks. * Undergo cardiometabolic biomarker assessments before and after the intervention. * Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic. * Provide biological samples to support the establishment of a biomarker repository for future research.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 29 Jul 2026
- Start date
- 3 Aug 2026
- Primary completion date
- 13 Jun 2027
- Lead sponsor
- Institute for Healthier Living Abu Dhabi
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07742917
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 3 Aug 2026 to the primary completion date, 13 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy)
- Transplant surgery within 12 months
- Surgery within 3 months prior to recruitment
Other illness
- Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation)
- Active psychiatric conditions, cognitive impairment, or mental health conditions affecting study participation
Age
- Aged under 25 years or over 50 years of age
Other
- BMI range under 30 kg/m2 and over 35 kg/m2
- Pregnancy
- Physical limitations preventing exercise participation
- Current enrolment in other lifestyle intervention programs
- Contraindication to MRI or DEXA imaging, including severe claustrophobia or need for sedation.
Who the study is looking for
- Emiratis residing in Abu Dhabi emirate
- Aged 25-50 years
- BMI 30-35 kg/m²
- Thiqa cardholder
- Previous participation in IFHAS screening
- Able to provide informed consent
- Participant in the Emirati Genome Programme
- No weight-loss medications (e.g., Ozempic, Saxenda, Wegovy) within 3 months of enrollment.
Age in the registry: 25 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute for Healthier Living Coordinator of this site? Confirm its status | Abu Dhabi | United Arab Emirates | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.